Results 251 to 260 of about 141,634 (350)

Congenital Esophageal Muscularis Propria Defect Found during Endoscopic Submucosal Dissection for Early Esophageal Cancer: A Case Report and Management

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Congenital esophageal muscularis propria defects are extremely rare, often complicating endoscopic submucosal dissection (ESD) for esophageal neoplasms. We report a 60‐year‐old man with early esophageal squamous cell carcinoma who underwent ESD.
Ying Liu   +4 more
wiley   +1 more source

Forward‐Viewing Endoscopic Ultrasound‐Guided Fine‐Needle Biopsy for a Hypopharyngeal Carcinoma Mimicking a Subepithelial Lesion: A Case Report

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Subepithelial lesions (SELs) of the head and neck have a low diagnostic yield with mucosal biopsy and carry a bleeding risk. Among endoscopic ultrasound–tissue acquisition (EUS‐TA) techniques, fine‐needle biopsy (FNB) provides higher specimen adequacy and diagnostic accuracy than fine‐needle aspiration (FNA).
Kakeru Otomo   +9 more
wiley   +1 more source

Clinicopathological Features of Superficial Non‐Ampullary Duodenal Epithelial Tumors Involving Brunner's Glands

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
Abstract Background and Aims Although Brunner's glands (BGs), located in the submucosa of the duodenum, may be involved by tumor cells of superficial non‐ampullary duodenal epithelial tumors (SNADETs), the detailed incidence and histopathological features have not yet been analyzed. This study aimed to clarify the histopathological relationship between
Kazuki Takayama   +15 more
wiley   +1 more source

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

open access: yesInternational Journal of Cancer, Volume 158, Issue 5, Page 1292-1301, 1 March 2026.
What's New? Patients with esophageal or gastroesophageal junction (GEJ) cancer with residual disease after treatment with neoadjuvant chemoradiotherapy (nCRT) and resection frequently experience poor survival. Improvements in outcome, however, may be possible using adjuvant treatment with nivolumab.
Rob H. A. Verhoeven   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy